What are the differences between Granulomatosis with Polyangiitis (GPA) and Polyarteritis Nodosa (PAN)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Granulomatosis with polyangiitis (GPA) and polyarteritis nodosa (PAN) are distinct vasculitis disorders with different clinical presentations, histological characteristics, and treatment approaches. The primary difference between GPA and PAN lies in the size of the vessels affected and the presence of granulomatous inflammation. GPA primarily affects small to medium vessels, particularly in the upper and lower respiratory tracts and kidneys, and is characterized by granulomatous inflammation, as noted in the 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis 1. In contrast, PAN affects medium-sized vessels throughout the body, sparing the lungs, and does not involve granuloma formation, as described in the 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of polyarteritis nodosa 1.

Some key differences between GPA and PAN include:

  • Vessel size: GPA affects small to medium vessels, while PAN affects medium-sized vessels
  • Granulomatous inflammation: GPA is characterized by granulomatous inflammation, while PAN is not
  • ANCA association: GPA is associated with anti-neutrophil cytoplasmic antibodies (ANCA), specifically PR3-ANCA in most cases, while PAN is not ANCA-associated
  • Clinical manifestations: GPA typically presents with sinusitis, bloody nasal discharge, pulmonary infiltrates, and glomerulonephritis, while PAN commonly manifests with abdominal pain, peripheral neuropathy, skin lesions, and hypertension

Treatment for both conditions involves immunosuppression, typically with corticosteroids and cyclophosphamide for induction, followed by maintenance therapy with less toxic agents like azathioprine or methotrexate, though specific regimens may vary based on disease severity and organ involvement 1. It is essential to note that the treatment approach for GPA and PAN may differ due to their distinct pathophysiological mechanisms and clinical presentations.

From the Research

Differences between Granulomatosis with Polyangitis (GPA) and Polyarteritis Nodosa (PAN)

  • GPA is a systemic necrotizing vasculitis that affects small- and medium-sized blood vessels, often associated with cytoplasmic ANCA 2.
  • GPA typically involves the upper and/or lower respiratory tract and kidneys, with clinical characteristics such as ear, nose, and throat manifestations, lung nodules, and rapidly progressive necrotizing glomerulonephritis 2.
  • In contrast, Polyarteritis Nodosa (PAN) is a systemic vasculitis that primarily affects medium-sized blood vessels, without granulomatosis or ANCA association.
  • PAN typically presents with symptoms such as hypertension, renal involvement, and gastrointestinal manifestations, but does not typically involve the respiratory tract or have granulomatous inflammation.

Key Distinctions

  • GPA is characterized by granulomatous inflammation and pauci-immune necrotizing glomerulonephritis, whereas PAN is characterized by necrotizing inflammation of medium-sized blood vessels without granulomatosis 3.
  • GPA often involves the respiratory tract, whereas PAN does not typically involve the respiratory tract.
  • GPA is often associated with ANCA, whereas PAN is not typically associated with ANCA.

Treatment and Prognosis

  • GPA treatment typically involves a combination of immunosuppressant drugs and corticosteroids, with a focus on inducing and maintaining remission 2, 4.
  • PAN treatment also involves immunosuppressant drugs and corticosteroids, but the specific treatment approach may differ depending on the severity and extent of disease.
  • GPA has a relatively high rate of relapse, with 50% of patients experiencing relapse within 5 years 2, whereas PAN has a more variable prognosis depending on the severity and extent of disease.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

From Head to Toe: Granulomatosis with Polyangiitis.

Radiographics : a review publication of the Radiological Society of North America, Inc, 2021

Related Questions

What changes in nerve conduction studies (NCS) and electromyography (EMG) are seen in a patient with Granulomatosis with Polyangiitis (GPA)?
What is the diagnosis and treatment for Granulomatosis with Polyangiitis (GPA)?
What is the current term for Granulomatosis with Polyangiitis (GPA) vasculitis?
Which of the following statements are correct regarding granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA): a) systemic symptoms occur in >50% of cases, mainly in GPA; b) ocular involvement occurs more frequently in EGPA; c) peripheral nervous system involvement occurs less frequently in EGPA; d) sinusitis is more common in EGPA; e) asthma is a main feature of GPA?
Which of the following vasculitides is not characterized by the presence of Anti-Neutrophil Cytoplasmic Antibodies (ANCA): a) Microscopic polyangiitis, b) Mixed cryoglobulinemia, c) Granulomatosis with polyangiitis (GPA) (formerly known as Wegener's granulomatosis), or d) Eosinophilic granulomatosis with polyangiitis (EGPA) (formerly known as Churg-Strauss syndrome)?
What is the diagnosis and management for a 2-year-old male with cryptorchidism (undescended testes)?
Can kids have a chronic Campylobacter (campylobacteriosis) infection?
Can ischemic bowel disease with lactic acidosis have normal computed tomography (CT) abdomen findings?
What is the diagnosis for a 19-year-old male presenting with interdigital (between the toes) blistering and associated xerosis (dry skin) for approximately one month?
What is the recommended dosing regimen for Prednisolone (a corticosteroid) for a 5-day course in an adult?
Why is vitamin B6 (Pyridoxine) given with Isoniazid (Isonicotinic Hydrazide)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.